Pharmacologic induction of heme oxygenase-1

Antioxidants and Redox Signaling

Volumn 9, Issue 12, 2007, Pages 2227-2239

  Li, Cheng ^a,b   Hossieny, Parastu ^a   Wu, Ben J ^a,b   Qawasmeh, Abdelqader ^a,b   Beck, Konstanze ^a,b   Stocker, Roland ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BM 15 0639; CAFFEIC ACID; CARNOSOL; CISPLATIN; CURCUMIN; D 4F; ETHYL FERULATE; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPRENALINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRONAPROXEN; PACLITAXEL; PEPTIDE DERIVATIVE; PICEATANNOL; POLYPHENOL DERIVATIVE; PROBUCOL; PROBUCOL DERIVATIVE; RAPAMYCIN; RESVERATROL; ROSEOLIC ACID; SULFORAPHANE; THIOCTIC ACID; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENZYME INDUCTION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE-1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, BIOLOGICAL; NITRIC OXIDE; PROBUCOL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 35848961446     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1783     Document Type: Review

References (141)

1. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, and Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274: 26071-26078, 1999.
2. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, and Tou J. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. J Biol Chem 275: 27694-27702, 2000.
3. Andreadi CK, Howells LM, Atherfold PA, and Manson MM. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol 69: 1033-1040, 2006.
4. Bach FH. Heme oxygenase-1: a therapeutic amplification funnel. FASEB J 19: 1216-1219, 2005.
5. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, and Motterlini R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371: 887-895, 2003.
6. Basseres DS and Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830, 2006.
7. Baur JA and Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
8. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, and Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006.
9. Bellosta S, Paoletti R, and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109: III50-III57, 2004.
10. Berndt G, Grosser N, Hoogstraate J, and Schrîder H. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci 25: 229-235, 2005.
11. Bouton C and Demple B. Nitric oxide-inducible expression of heme oxygenase-1 in human cells: translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. J Biol Chem 275: 32688-32693, 2000.
12. Brown J, Reading SJ, Jones S, Fitchett CJ, Howl J, Martin A, Longland CL, Michelangeli F, Dubrova YE, and Brown CA. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 80: 37-45, 2000.
13. Chang L and Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
14. Chen CY, Jang JH, Li MH, and Surh YJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 331: 993-1000, 2005.
15. Chen JC, Huang KC, and Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 18: 32-39, 2006.
16. Chen JC, Chen Y, Lin JH, Wu JM, and Tseng SH. Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res 26: 1237-1245, 2006.
17. Choi AM and Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 15: 9-19, 1996.
18. Choi BM, Kim YM, Jeong YR, Pae HO, Song CE, Park JE, Ahn YK, and Chung HT. Induction of heme oxygenase-1 is involved in anti-proliferative effects of paclitaxel on rat vascular smooth muscle cells. Biochem Biophys Res Commun 321: 132-137, 2004.
19. Choi BM, Kim HJ, Oh GS, Pae HO, Oh H, Jeong S, Kwon TO, Kim YM, and Chung HT. 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose protects rat neuronal cells (Neuro 2A) from hydrogen peroxide-mediated cell death via the induction of heme oxygenase-1. Neurosci Lett 328: 185-189, 2002.
20. Choi HS and Moore DD. Induction of c-fos and c-jun gene expression by phenolic antioxidants. Mol Endocrinol 7: 1596-1602, 1993.
21. Chun YJ, Kim MY, and Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262: 20-24, 1999.
22. Chung SW, Chen YH, and Perrella MA. Role of ets-2 in the regulation of heme oxygenase-1 by endotoxin. J Biol Chem 280: 4578-4584, 2005.
23. Claria J and Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 92: 9475-9479, 1995.
24. Corder R, Mullen W, Khan NQ, Marks SC, Wood EG, Carrier MJ, and Crozier A. Oenology: red wine procyanidins and vascular health. Nature 444: 566, 2006.
25. Delmas D, Lancon A, Colin D, Jannin B, and Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 7: 423-442, 2006.
26. Deng YM, Wu BJ, Witting PK, and Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 110: 1855-1860, 2004.
27. Dhakshinamoorthy S, Jain AK, Bloom DA, and Jaiswal AK. BACH1 competes with NRF2 leading to negative regulation of are-mediated NAD(P)H: quinone oxidoreductase1 gene expression and induction in response to antioxidants. J Biol Chem 280: 16891-16900, 2005.
28. Dinkova-Kostova AT, Massiah MA, Bozak RE, Hicks RJ, and Talalay P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc Natl Acad Sci U S A 98: 34040-33409, 2001.
29. Duckers HJ, Boehm M, True AL, Yet S-F, San H, Park JL, Webb RC, Lee M-E, Nable GJ, and Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7: 693-698, 2001.
30. Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol 195: 373-382, 2003.
31. Durante W, Kroll MH, Christodoulides N, Peyton KJ, and Schafer AI. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res 80: 557-564, 1997.
32. Eggler AL, Liu G, Pezzuto JM, van Breemen RB, and Mesecar AD. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S A 102: 10070-10075, 2005.
33. Endo A and Hasumi K. HMG-CoA reductase inhibitors. Nat Prod Rep 10: 541-550, 1993.
34. Foresti R, Hoque M, Monti D, Green CJ, and Motterlini R. Differential activation of heme oxygenase-1 by chalcones and rosolic acid in endothelial cells. J Pharmacol Exp Ther 312: 686-693, 2005.
35. Francis SH and Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36: 275-328, 1999.
36. Fruebis J, Steinberg D, Dresel HA, and Carew TA. A comparison of the antiatherogenic effects of probucol and a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 94: 392-398, 1994.
37. Fukao H, Ijiri Y, Miura M, Hashimoto M, Yamashita T, Fukunaga C, Oiwa K, Kawai Y, Suwa M, and Yamamoto J. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinol 15: 441-446, 2004.
38. Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, Bertelli A, and Maulik N. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44: 43-49, 2006.
39. Garg UC and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83: 1774-1777, 1989.
40. Goh SS, Woodman OL, Pepe S, Cao AH, Qin C, and Ritchie RH. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal 9: 101-113, 2007.
41. Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, and Schröder H. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 308: 956-960, 2003.
42. Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schürger S, Wijayanti N, Immenschuh S, and Schröder H. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 37: 2064-2071, 2004.
43. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002.
44. Grundemar L and Ny L. Pitfalls using metalloporphyrins in carbon monoxide research. Trends Pharmacol Sci 18: 193-195, 1997.
45. Harris LK, Mann GE, Ruiz E, Mushtaq S, and Leake DS. Ascorbate does not protect macrophages against apoptosis induced by oxidised low density lipoprotein. Arch Biochem Biophys 455: 68-76, 2006.
46. Harrison EM, McNally SJ, Devey L, Garden OJ, Ross JA, and Wigmore SJ. Insulin induces heme oxygenase-1 through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in renal cells. FEBS J 273: 2345-2356, 2006.
47. Hartsfield CL, Alam J, Cook JL, and Choi AM. Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide. Am J Physiol 273: L980-L988, 1997.
48. Hickey MJ, Sharkey KA, Sihota EG, Reinhardt PH, Macmicking JD, Nathan C, and Kubes P. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J 11: 955-964, 1997.
49. Hill-Kapturczak N, Thamilselvan V, Liu F, Nick HS, and Agarwal A. Mechanism of heme oxygenase-1 gene induction by curcumin in human renal proximal tubule cells. Am J Physiol Renal Physiol 281: F851-F859, 2001.
50. Hong F, Freeman ML, and Liebler DC. Identification of sensor cysteines in human keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 18: 1917-1926, 2005.
51. Hong F, Sekhar KR, Freeman ML, and Liebler DC. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J Biol Chem 280: 31768-31775, 2005.
52. Hsu M, Muchova L, Morioka I, Wong RJ, Schröder H, and Stevenson DK. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun 343: 738-744, 2006.
53. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 3: 31-36, 1989.
54. Ignarro LJ. Nitric oxide: a novel signal transduction mechanism for transcellular communication. Hypertension 16: 477-483, 1990.
55. Ignarro LJ, Napoli C, and Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90: 21-28, 2002.
56. Ignarro LJ, Cirino G, Casini A, and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 34: 879-886, 1999.
57. Immenschuh S, Hinke V, Ohlmann A, Gifhorn-Katz S, Katz N, Jungermann K, and Kietzmann T. Transcriptional activation of the haem oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J 334: 141-146, 1998.
58. Inamdar NM, Ahn YI, and Alam J. The heme-responsive element of the mouse heme oxygenase-1 gene is an extended AP-1 binding site that resembles the recognition sequences for MAF and NF-E2 transcription factors. Biochem Biophys Res Commun 221: 570-576, 1996.
59. Ishikawa K, Sugawara D, Goto J, Watanabe Y, Kawamura K, Shiomi M, Itabe H, and Maruyama Y. Heme oxygenase-1 inhibits atherogenesis in Watanabe heritable hyperlipidemic rabbits. Circulation 104: 1831-1836, 2001.
60. Itoh K, Wakabayashi N, Katoh Y, Ishii T, O'Connor T, and Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 8: 379-391, 2003.
61. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Neh2 domain. Genes Dev 13: 76-86, 1999.
62. Johnson GL and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
63. Juan SH, Cheng TH, Lin HC, Chu YL, and Lee WS. Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem Pharmacol 69: 41-48, 2005.
64. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, and Chau LY. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 104: 1519-1525, 2001.
65. Kabe Y, Ando K, Hirao S, Yoshida M, and Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7: 395-403, 2005.
66. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
67. Karin M, Liu Z, and Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
68. Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, Han J, Agarwal A, and Kong AN. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma hepG2 cells. Cancer Res 66: 8804-8813, 2006.
69. Kiemer AK, Bildner N, Weber NC, and Vollmar AM. Characterization of heme oxygenase 1 (heat shock protein 32) induction by atrial natriuretic peptide in human endothelial cells. Endocrinology 144: 802-812, 2003.
70. Kronke G, Bochkov VN, Huber J, Gruber F, Bluml S, Furnkranz A, Kadl A, Binder BR, and Leitinger N. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem 278: 51006-51014, 2003.
71. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, and Abraham NG. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111: 3126-3134, 2005.
72. Kuo ML, Huang TS, and Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta 1317: 95-100, 1996.
73. Kurumbail RG, Kiefer JR, and Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Curr Opin Struct Biol 11: 752-760, 2001.
74. Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, and Abraham NG. Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A 91: 5987-5991, 1994.
75. Lee TS, Chang CC, Zhu Y, and Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110: 1296-1302, 2004.
76. Liu XM, Peyton KJ, Ensenat D, Wang H, Schafer AI, Alam J, and Durante W. Endoplasmic reticulum stress stimulates heme oxygenase-1 gene expression in vascular smooth muscle: role in cell survival. J Biol Chem 280: 872-877, 2005.
77. Liu Y, MoenneLoccoz P, Loehr TM, and OrtizdeMontellano PR. Heme oxygenase-1, intermediates in verdoheme formation and the requirement for reduction equivalents. J Biol Chem 272: 6909-6917, 1997.
78. Loboda A, Jazwa A, Jozkowicz A, Dorosz J, Balla J, Molema G, and Dulak J. Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells. Atherosclerosis 187: 26-30, 2006.
79. Lusis AJ. Atherosclerosis. Nature 407: 233-241, 2000.
80. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554, 1997.
81. Maines MD and Gibbs PEM. 30 years of heme oxygenase: from a "molecular wrecking ball" to a "mesmerizing" trigger of cellular events. Biochem Biophys Res Commun 338: 568-577, 2005.
82. Marquis JC and Demple B. Complex genetic response of human cells to sublethal levels of pure nitric oxide. Cancer Res 58: 3435-3440, 1998.
83. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, and Cuadrado A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279: 8919-8929, 2004.
84. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, and FitzGerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 105: 1473-1482, 2000.
85. Mellion BT, Ignarro LJ, Myers CB, Ohlstein EH, Ballot BA, Hyman AL, and Kadowitz PJ. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 23: 653-664, 1983.
86. Motterlini R, Foresti R, Intaglietta M, and Winslow RM. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol Heart Circ Physiol 270: H107-H114, 1996.
87. Motterlini R, Foresti R, Bassi R, and Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28: 1303-1312, 2000.
88. Napoli C and Ignarro LJ. Nitric oxide, and atherosclerosis. Nitric Oxide 5: 88-97, 2001.
89. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, and Fierro IM. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 289: C557-C563, 2005.
90. Nguyen T, Sherratt PJ, and Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233-260, 2003.
91. Oberle S, Abate A, Grosser N, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, and Schrîder H. Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate. Biochem Biophys Res Commun 290: 1539-1544, 2002.
92. Ogborne RM, Rushworth SA, and O'Connell MA. α-Lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler Thromb Vasc Biol 25: 2100-2105, 2005.
93. Ogborne RM, Rushworth SA, Charalambos CA, and O'Connell MA. Haem oxygenase-1: a target for dietary antioxidants. Biochem Soc Trans 32: 1003-1005, 2004.
94. Ortiz de Montellano PR. The mechanism of heme oxygenase. Curr Opin Chem Biol 4: 221-227, 2000.
95. Otterbein LE, Soares MP, Yamashita K, and Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24: 449-455, 2003.
96. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, and Gilroy DW. 15-Epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 200: 69-78, 2004.
97. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25: 6717-6730, 2006.
98. Polte T, Hemmerle A, Berndt G, Grosser N, Abate A, and Schröder H. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med 32: 56-63, 2002.
99. Prawan A, Kundu JK, and Surh YJ. Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal 7: 1688-1703, 2005.
100. Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ, and Choi AM. Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstream antioxidant-responsive elements (ARE). Mol Med 1: 827-837, 1995.
101. Prochaska HJ, De Long MJ, and Talalay P. On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. Proc Natl Acad Sci USA 82: 8232-8236, 1985.
102. Qi YF, Dong LW, Pan CS, Zhang J, Geng B, Zhao J, and Tang CS. Adrenomedullin induces heme oxygenase-1 gene expression and cGMP formation in rat vascular smooth muscle cells. Peptides 26: 1257-1263, 2005.
103. Rosenberg DW and Kappas A. Characterization of heme oxygenase in the small intestinal epithelium. Arch Biochem Biophys 274: 471-480, 1989.
104. Ryter SW, Alam J, and Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86: 583-650, 2006.
105. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, and Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243: 388-390, 1989.
106. Sassa S. Why heme needs to be degraded to iron, biliverdin IX-alpha, and carbon monoxide? Antioxid Redox Signal 6: 819-824, 2004.
107. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, and Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39: 610-616, 2002.
108. Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ, and Motterlini R. Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol Pharmacol 61: 554-561, 2002.
109. Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, and Calabrese V. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Antioxid Redox Signal 6: 811-818, 2004.
110. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, and Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003.
111. Stenton SB, Partovi N, and Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 44: 769-786, 2005.
112. Stewart D, Killeen E, Naquin R, Alam S, and Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem 278: 2396-2402, 2003.
113. Stocker R and Perrella MA. Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation 114: 2178-2189, 2006.
114. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, and Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046, 1987.
115. Sun J, Brand M, Zenke Y, Tashiro S, Groudine M, and Igarashi K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci U S A 101: 1461-1466, 2004.
116. Sun J, Kim SJ, Park MK, Kim HJ, Tsoy I, Kang YJ, Lee YS, Seo HG, Lee JH, and Chang KC. Selective activation of adrenergic β1 receptors induces heme oxygenase 1 production in RAW264.7 cells. FEBS Lett 579: 5494-5500, 2005.
117. Suzuki H, Tashiro S, Sun J, Doi H, Satomi S, and Igarashi K. Cadmium induces nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene. J Biol Chem 278: 49246-49253, 2003.
118. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, and Russell ME. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107: 559-564, 2003.
119. Tardif J-C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, and de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 337: 365-372, 1997.
120. Tardif JC, Gregoire J, Schwartz L, Title L, Laramee L, Reeves F, Lesperance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, and Guertin MC. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107: 552-558, 2003.
121. Tenhunen R, Marver HS, and Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci U S A 61: 748-755, 1968.
122. 2 in endothelial cells. Am J Physiol 276: H1493-H1501, 1999.
123. Thompson GR and Barter PJ. Clinical lipidology at the end of the millennium. Curr Opin Lipidol 10: 521-526, 1999.
124. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 8: 205-215, 1996.
125. Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, and Schafer AI. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 104: 2710-2715, 2001.
126. Visner GA, Lu F, Zhou H, Liu J, Kazemfar K, and Agarwal A. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin. Circulation 107: 911-916, 2003.
127. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW, and Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A 101: 2040-2045, 2004.
128. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, and Lindsay J. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 44: 1386-1392, 2004.
129. Wang J and Ortiz de Montellano PR. The binding sites on human heme oxygenase-1 for cytochrome p450 reductase and biliverdin reductase. J Biol Chem 278: 20069-20076, 2003.
130. Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C, Leger JJ, Lackowska B, Grochot A, Bojkowska K, Ratajska A, Kieda C, Szala S, Dulak J, and Jozkowicz A. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 169: 2181-2198, 2006.
131. Wilson T, Knight TJ, Beitz DC, Lewis DS, and Engen RL. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 59: 15-21, 1996.
132. Witting PK, Pettersson K, Letters J, and Stocker R. Site-specific anti-atherogenic effect of probucol in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 20: e26-e33, 2000.
133. Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, Croft KD, Mori TA, Tanous D, Adams MR, Lau AK, and Stocker R. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 203: 1117-1127, 2006.
134. Wu L and Juurlink BH. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 19: 1819-1825, 2001.
135. Wullschleger S, Loewith R, and Hall MN. TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
136. Wung BS, Hsu MC, Wu CC, and Hsieh CW. Piceatannol upregulates endothelial heme oxygenase-1 expression via novel protein kinase C and tyrosine kinase pathways. Pharmacol Res 53: 113-122, 2006.
137. Yet SF, Pellacani A, Patterson C, Tan L, Folta SC, Foster L, Lee WS, Hsieh CM, and Perrella MA. Induction of heme oxygenase-1 expression in vascular smooth muscle cells: a link to endotoxic shock. J Biol Chem 272: 4295-4301, 1997.
138. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B, Melo LG, Zhang L, Ingwall JS, Dzau VJ, Lee ME, and Perrella MA. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 89: 168-173, 2001.
139. Yoshida T and Kikuchi G. Sequence of the reaction of heme catabolism catalyzed by the microsomal heme oxygenase system. FEBS Lett 48: 256-261, 1974.
140. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, and Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280: 30091-30099, 2005.
141. Zhou H, Liu H, Porvasnik SL, Terada N, Agarwal A, Cheng Y, and Visner GA. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 86: 62-71, 2006.